Dharmesh Mehta (@dharmeshm1008) header
Dharmesh Mehta (@dharmeshm1008) profile picture

chasing that one big trade! Trader turned Investor Not a financial advisor.

Ahmedabad
Joined October 2017
Photo by Dharmesh Mehta (@dharmeshm1008)Photo by Dharmesh Mehta (@dharmeshm1008)Photo by Dharmesh Mehta (@dharmeshm1008)Photo by Dharmesh Mehta (@dharmeshm1008)Photo by Dharmesh Mehta (@dharmeshm1008)Photo by Dharmesh Mehta (@dharmeshm1008)Photo by Dharmesh Mehta (@dharmeshm1008)Photo by Dharmesh Mehta (@dharmeshm1008)Photo by Dharmesh Mehta (@dharmeshm1008)Photo by Dharmesh Mehta (@dharmeshm1008)
Made highest profit till now in my trading career. 10lac+ 🥂
13
93
18,763
Spotted an interesting deal: ASK Automotive promoters have picked up roughly a 20% stake in Asston Pharmaceuticals through a preferential issue at ₹115/share. Another notable trade by them was Mahamaya Steel, entered at ₹300 in June 2025, which has since surged to ₹1400. #invested
1
2
4
343
Oh boi what a Diwali sale 😅 Picked up Granules, Skipper, MM Forgings, and Gufic Biosciences. Disclaimer: Not investment advice.
1
3
416
Investor Girish Gulati picks up a 1% fresh stake in both Gufic Bioscience and Kavveri Defence, according to the September 2026 shareholding pattern (SHP).
1
2
7
646
3P India Equity Fund of Prashant Jain appears in the September 2026 SHP of Carraro India with a 3.45% stake.
1
4
450
Purnima Ashwin Desai (Promoter of Aether Industries) has invested in Borona Weaves (1% stake). Both Surat based. Big promoter backing small caps is one of my favorite hunting grounds. Similar to KIMS founder backing Sai Parental, these bets by seasoned industry folks are always worth tracking closely. Disclaimer: No position in the stock; currently just studying.
1
6
632
Zerodha Broking enters Silchar Tech with a 1.36% stake (Sept 2026 shareholding data)
1
7
809
MV Electrosystems new ATH! Banger move
MV Electrosystems is on fire 🔥 Keep in mind, propulsion revenue is expected to start showing up from Nov 2026, as per management. So don’t FOMO into it, there will be pullbacks. This is not a short term play. #invested
4
376
Good to see Smallcap World Fund in Diamond Power Sep 2026 SHP. 👀 One of my favourite FIIs to track. Always interesting to see where they’re placing their bets.
Crazy move in Diamond Power 🔥 Almost a doubler in less than 2 months. #diacabs
10
482
Swan Defence at ₹3000 Up 50% in just 4 months, and I believe there’s still a long way to go. Disclaimer: This is not financial advice.
Swan Defence & Heavy Industries CMP: 2000 • Ex-Reliance Naval, acquired through bankruptcy resolution. • One of India’s largest shipbuilding capacities. • Controlled by Nikhil Merchant-led Swan Group. • Came on my radar after Zerodha invested.
5
429
Shanti Inorganics new ATH!
Bought Shanti Inorganics CMP: ₹196 A small-scale chemical producer based out of Gujarat is laying the groundwork for a major capacity expansion. With aggressive Capex plans and a move into higher-value chemical grades. Thesis below 👇
4
567
Bought Shanti Inorganics CMP: ₹196 A small-scale chemical producer based out of Gujarat is laying the groundwork for a major capacity expansion. With aggressive Capex plans and a move into higher-value chemical grades. Thesis below 👇
1
13
2
54
7,490
Big Investors & Key Backers ▪️ Members of the Polycab promoter family recently acquired a 1.4% stake. ▪️ R R Family Trust acquired shares from the open market at ₹158
2
3
539
Risks to Watch Out For ▪️ Project Execution: Managing a expansion project that is larger than the company's current annual revenue. ▪️ Safety & Handling: Operates with hazardous gases like ammonia and sulphur dioxide.
2
435
Sai Parenterals CMP : ₹522 Entries at ₹496 and ₹530 Sai Parenterals Limited is a Hyderabad-based global pharmaceutical company specializing in injectable formulations. It is transforming into an international generic formulations and CDMO engine. Thesis below 👇
1
1
10
1,218
Key Risks To Watch While execution remains strong, monitor these risk metrics: ▪️ Execution & Ramp-Up Timelines: Commercial production schedules for the Saicriti facility and Adelaide plant must stay on track. ▪️ Regulatory Accreditations: Obtaining EU-GMP/USFDA approvals for new facilities without audit delays. ▪️ Peak Debt Levels: Capex execution will peak balance sheet leverage in FY27, with deleveraging expected from FY28 onwards.
1
1
110
Summary & Outlook ▪️ Execution Phase: FY27 is a critical transition year focused on plant commissioning and volume migration. ▪️ Monetization Engine: FY28 marks the core inflection point as in-house manufacturing, Australia facility operations, and high-margin export CDMO contracts fully kick in.
104